112 related articles for article (PubMed ID: 23780849)
1. Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology.
Idowu MO
Cancer Cytopathol; 2013 Oct; 121(10):540-3. PubMed ID: 23780849
[No Abstract] [Full Text] [Related]
2. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
3. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
4. Chasing mutations in the epidermal growth factor in lung cancer.
Dowell JE; Minna JD
N Engl J Med; 2005 Feb; 352(8):830-2. PubMed ID: 15728818
[No Abstract] [Full Text] [Related]
5. EGFR mutations and sensitivity to gefitinib.
Sorscher SM
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15371587
[No Abstract] [Full Text] [Related]
6. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
7. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Lai RS; Xie L; Shen LS; He YM; Zhu CL
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
[No Abstract] [Full Text] [Related]
8. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
9. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Morabito A; Costanzo R; Rachiglio AM; Pasquale R; Sandomenico C; Franco R; Montanino A; De Lutio E; Rocco G; Normanno N
J Thorac Oncol; 2013 Jul; 8(7):e59-60. PubMed ID: 23774386
[No Abstract] [Full Text] [Related]
10. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Mitsudomi T
Lancet Oncol; 2011 Aug; 12(8):710-1. PubMed ID: 21783418
[No Abstract] [Full Text] [Related]
13. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Couzin J
Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
[No Abstract] [Full Text] [Related]
14. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Shih JY; Gow CH; Yang PC
N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
[No Abstract] [Full Text] [Related]
15. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
Jänne PA
J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470
[No Abstract] [Full Text] [Related]
16. EGFR mutation and response of lung cancer to gefitinib.
Toyooka S; Kiura K; Mitsudomi T
N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872
[No Abstract] [Full Text] [Related]
17. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Hata A; Masago K; Katakami N; Imai Y; Yatabe Y
J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783
[No Abstract] [Full Text] [Related]
18. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
19. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Langer CJ
J Clin Oncol; 2009 Mar; 27(9):1350-4. PubMed ID: 19224840
[No Abstract] [Full Text] [Related]
20. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
